Cancer Institute and Hospital, Chinese Academy of Medical Sciences: Colorectal Neoplasms trials

The registry lists 24 Colorectal Neoplasms studies with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor. 18 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 11Phase 3 1No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRCRecruitingNCT07724223Phase 2
• Distribution and Analysis of Metastatic Lymph Nodes in Colorectal Cancer Patients (DIAMOND)Not yet recruitingNCT07306390
• Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal CancerNot yet recruitingNCT07286695Phase 2
• Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal CancerRecruitingNCT06904677
• Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal CancerNot yet recruitingNCT06858969Phase 2
• Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal CancerNot yet recruitingNCT06858956
• ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal CancerRecruitingNCT06543836Phase 2
• Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal CancerRecruitingNCT06405139Phase 2
• Short-term and Long-term Outcomes of Colorectal Cancer Treated With Natural Orifice Specimen Extraction Surgery : a National Registry-based StudyRecruitingNCT06350370Not applicable
• Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC PatientsRecruitingNCT06202001Phase 1/2
• Study on the No.253 Lymph Node Metastasis Patterns in Left-Sided Colon and Rectal CancerRecruitingNCT06135571
• Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal CancerRecruitingNCT06114420
• XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRCRecruitingNCT05970302Phase 2
• Safety and Feasibility of Laparoscopic Intracorporeal Anastomosis for Colorectal Surgery- A Multiple Center Real World StudyRecruitingNCT05911152
• Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal CancerRecruitingNCT05815290Phase 2
• Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon CancerNot yet recruitingNCT05730595Not applicable
• Early Screening of Colorectal Cancer Based on Plasma Multi-omics Combining With Artificial IntelligenceRecruitingNCT05587452
• Safety Study of Totally Laparoscopic Resection With Natural Orifice Specimen Extraction (NOSE) for Rectosigmoid CancerRecruitingNCT02635503Phase 3
• A Multicenter Study on the Safety and Functionality Evaluation of Anastomotic Redo SurgeryCompletedNCT07279961
• Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC PatientsActive, not recruitingNCT06403709Phase 2
• Prognosis Stratification for pT4bN0M0 Colorectal Cancer Following Multivisceral ResectionCompletedNCT06115837
• Multivisceral Radical Resection for Surgical T4b Colorectal Cancer: Propensity Score-matched Study Comparing the the Laparoscopic and Open ApproachesCompletedNCT05707598
• A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic TherapyStatus unknownNCT05511051Phase 2
• Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105Status unknownNCT05289726Phase 2